Accrued Expense	9 Months Ended
Sep. 30, 2023
Accrued Expense [Abstract]
Accrued Expense	6. Accrued Expense As of September 30, 2023, current liabilities included accrued expenses of $1.0 million, comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, professional and consulting fees of $0.2 million, drug manufacturing development and testing services of $0.2 million, expenses related to our clinical trial for prexigebersen in AML of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2022, current liabilities included accrued expenses of $0.9 million, comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, drug manufacturing development and testing services of $0.2 million, professional and consulting fees of $0.1 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million.

Accrued Expense

9 Months Ended

Sep. 30, 2023

6. Accrued Expense

As of September 30, 2023, current liabilities included accrued expenses of $1.0 million, comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, professional and consulting fees of $0.2 million, drug manufacturing development and testing services of $0.2 million, expenses related to our clinical trial for prexigebersen in AML of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2022, current liabilities included accrued expenses of $0.9 million, comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, drug manufacturing development and testing services of $0.2 million, professional and consulting fees of $0.1 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million.